Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCHERING-PLOUGH

(SGP)
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock

02/27/2009 | 01:10pm EST

KENILWORTH, N.J., Feb. 27 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on May 26, 2009, to shareholders of record at the close of business on May 1, 2009. As of Jan. 31, 2009, there were 1,626,412,285 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on May 15, 2009, to holders of record at the close of business on May 1, 2009. There are currently 10 million shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation


ę PRNewswire 2009
All news about SCHERING-PLOUGH
2009SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India
PR
2009SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary En..
PR
2009SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Letter Regard..
PR
2009SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices
PR
2009SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter
PR
2009SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Con..
PR
2009SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earnings
PR
2009SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcu..
PR
2009SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible ..
PR
2009SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Stu..
PR
More news